<DOC>
	<DOCNO>NCT02579681</DOCNO>
	<brief_summary>The primary objective ( ) study assess BG00012 ( dimethyl fumarate ) treatment effect cognition 2 year period RRMS patient . The secondary objective study assess BG00012 treatment effect cognition , predictor cognitive impairment , clinical efficacy , patient report outcome ( PRO ) : depression , fatigue , quality life , work social life activity .</brief_summary>
	<brief_title>Study Assessing Cognition Relapsing Remitting Multiple Sclerosis ( RRMS ) Patients Treated With BG00012</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Must confirm diagnosis RRMS accord McDonald criterion ( Polman , Reingold et al . 2005 ) . Must baseline EDSS 0.0 5.0 , inclusive . Must experience least 1 relapse within 12 month prior randomization , prior brain MRI demonstrate lesion ( ) consistent MS , show evidence gadoliniumenhancing lesion ( ) brain MRI perform within 6 week prior randomization . Key Candidates exclude study entry follow exclusion criterion exist time screening : Primary progressive , secondary progressive , progressive relapsing MS , define Lublin Reingold ( Lublin Reingold 1996 ) Severe depression ( MADRS score &gt; 34 ) ( Montgomery Asberg 1979 ) History malignancy ( except basal cell carcinoma completely excise prior study enrollment ) An MS relapse occur within 30 day prior inclusion AND/OR participant stabilize previous relapse prior inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cognition</keyword>
	<keyword>Tecfidera</keyword>
	<keyword>RRMS</keyword>
	<keyword>BG00012</keyword>
</DOC>